1. Inhibition of experimental neointimal hyperplasia and neoatherosclerosis by local, stent- mediated delivery of everolimus 
Hugh Q. Zhao, PhD, Alexander Nikanorov, MD, PhD, Renu Virmani, MD, Lewis B. Schwartz, MD 
Journal of Vascular Surgery 
Volume 56, Issue 6, Pages (December 2012)
DOI: /j.jvs
Copyright © 2012 Society for Vascular Surgery Terms and Conditions

2. Fig 1 The Dynalink-E everolimus-eluting self-expanding stent.
Journal of Vascular Surgery  , DOI: ( /j.jvs )
Copyright © 2012 Society for Vascular Surgery Terms and Conditions

3. Fig 2
In vivo profile of everolimus release from the drug-polymer coating on the Dynalink-E nitinol self-expanding stent.
Journal of Vascular Surgery  , DOI: ( /j.jvs )
Copyright © 2012 Society for Vascular Surgery Terms and Conditions

4. Fig 3
In vivo everolimus concentrations in whole blood, stented arteries, and unstented (adjacent) arterial tissues after implantation of the Dynalink-E drug-eluting stent (DES). LLOQ, Lower limit of quantitation.
Journal of Vascular Surgery  , DOI: ( /j.jvs )
Copyright © 2012 Society for Vascular Surgery Terms and Conditions

5. Fig 4
Whole-mount example histophotomicrographs of overlapped bare metal stent (BMS) or drug-eluting stent (DES) in porcine iliac arteries after 3 months (left panels), 6 months (middle panels), and 12 months (right panels). Sections are stained with toluidine blue and basic fuchsin.
Journal of Vascular Surgery  , DOI: ( /j.jvs )
Copyright © 2012 Society for Vascular Surgery Terms and Conditions

6. Fig 5
Histologic examples of stent-inducted neoatherosclerosis. a, Bare metal stent (BMS) at 3 months. Note the presence of severe neoatherosclerosis, including cholesterol clefts visible as void spaces, surrounding foamy cell accumulation, and fat infiltration. b, BMS at 6 months. c, BMS at 12 months. d, Drug-eluting stents (DES) at 12 months. Sections were stained with toluidine blue basic fuchsin.
Journal of Vascular Surgery  , DOI: ( /j.jvs )
Copyright © 2012 Society for Vascular Surgery Terms and Conditions